Compare Moderna, Inc. (MRNA) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Paychex, Inc. — how do they compare? Moderna, Inc. trades at $219.06 (market cap $78.65B), while Paychex, Inc. trades at $104.74 (market cap $37.19B). The key difference: Moderna, Inc. is far larger — about 2.1× Paychex, Inc.'s market cap, and Paychex, Inc. pays a 4.56% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Paychex, Inc. for 56 Days on average.
| MRNA | PAYX | |
|---|---|---|
Market Cap | $78.65B | $37.19B |
Volume | 37,373,437 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $203.46 | $128.59 |
52-Week Low | $22.36 | $85.57 |
Typical Hold Time | 59 Days | 56 Days |
Enterprise Value | $74.80B | $40.87B |
Dividend Yield | — | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and 47.06% ROE, but valuation ratios like P/E of 20.73 and P/S of 5.67 appear elevated. Recent news highlights mixed sentiment, with earnings outperformance offset by concerns over dividend sustainability and labor market cooling.
The outlook is cautious; while fundamentals remain solid with consistent revenue growth, high debt levels and bearish technicals pose risks. Analyst consensus leans hold with a $111 price target, suggesting limited upside. Key opportunities include dividend yield and PEO growth, but investors face headwinds from economic sensitivity and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
